Role of Fibrocytes in the Bronchial Remodelling of Chronic Obstructive Pulmonary Disease

NCT01692444 | Completed

• 2 other identifiers: CHUBX 2011/342012-A00571-42
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Airway remodelling is an abnormal tissue repair following bronchial inflammation, which contributes to none reversible pathological features, such as bronchial and peri-bronchial fibrosis. It also influences the prognosis of Chronic Obstructive Pulmonary Disease (COPD) and its mechanisms remain largely unknown. The role of fibrocytes has been demonstrated in the pathophysiology of asthma, lung fibrosis or pulmonary hypertension. However, the recruitment of blood fibrocytes and their involvement in COPD airway remodelling remain unknown. The main objective of the study is to analyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients with different stages of COPD compared to control subjects.

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

Chronic Obstructive Pulmonary Disease; Fibrosis; Fibroblast; Lung attenuation; Pletysmography

Outcome Measures

Primary Outcomes (1)

• Increased number of peri-bronchial and blood circulating fibrocytes gradually in each stages of COPD and compared to control subjects.

  Lung tissues and blood samples will be collected at inclusion visit during surgery (Day 0)

Secondary Outcomes (3)

• Characterization of fibrocytes: expression of chemokines receptors, Toll Like Receptors, HLA class II

  Lung tissues and blood samples will be collected at inclusion visit during surgery (Day 0)

• Correlation between lung attenuation and the number of fibrocytes

  Assessed one year after inclusion visit (i.e. surgery date =Day 0)

• Correlation between plethysmography and the number of fibrocytes.

  Assessed one year after inclusion visit (i.e. surgery date = Day 0)

Study Arms (3)

COPD

EXPERIMENTAL

15 patients with COPD from 1 to 4 according to the GOLD 2011

Biological: analyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients

Non smoker Control

PLACEBO COMPARATOR

15 patients without COPD and no smoking history

Biological: analyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients

Smoker Control

ACTIVE COMPARATOR

15 patients without COPD but a smoking history

Biological: analyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients

Interventions

analyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients BIOLOGICAL

analyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients

COPD; Non smoker Control; Smoker Control

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female aged more than 40 yr
• Patient needed a thoracic surgery such as lobectomy for cancer or lung transplantation or lung reduction volume surgery.
• COPD group: diagnostic of COPD and differentiation of the stage from 1 to 4 according to the GOLD guidelines.
• Control group: subjects with normal lung function testing and no chronic symptoms (cough or expectoration). Subjects will be separated in 2 groups according to smoking history (Never smokers, smokers (former or current) and paired to patients according to age and sex.
• with a written informed consent

You may not qualify if:

• Subject without any social security or health insurance
• Asthma, lung fibrosis or idiopathic pulmonary hypertension
• Chronic viral infections (hepatitis, HIV)
• Pregnant woman or breastfeeding
• Subject included for cancer surgery with a Pn0 diagnosis not confirmed after the intervention.

Sponsors & Collaborators

• University Hospital, Bordeaux: lead

Study Sites (1)

University hospital of Bordeaux, Hôpital du Haut Lévêque

Pessac, 33604, France

Location

Related Publications (3)

• Dupin I, Thumerel M, Maurat E, Coste F, Eyraud E, Begueret H, Trian T, Montaudon M, Marthan R, Girodet PO, Berger P. Fibrocyte accumulation in the airway walls of COPD patients. Eur Respir J. 2019 Sep 5;54(3):1802173. doi: 10.1183/13993003.02173-2018. Print 2019 Sep.

  PMID: 31196946 RESULT

• Eyraud E, Maurat E, Sac-Epee JM, Henrot P, Zysman M, Esteves P, Trian T, Dupuy JW, Leipold A, Saliba AE, Begueret H, Girodet PO, Thumerel M, Hustache-Castaing R, Marthan R, Levet F, Vallois P, Contin-Bordes C, Berger P, Dupin I. Short-range interactions between fibrocytes and CD8+ T cells in COPD bronchial inflammatory response. Elife. 2023 Jul 26;12:RP85875. doi: 10.7554/eLife.85875.

  PMID: 37494277 DERIVED

• Henrot P, Beaufils F, Thumerel M, Eyraud E, Boudoussier A, Begueret H, Maurat E, Girodet PO, Marthan R, Berger P, Dupin I, Zysman M. Circulating fibrocytes as a new tool to predict lung cancer progression after surgery? Eur Respir J. 2021 Dec 9;58(6):2101221. doi: 10.1183/13993003.01221-2021. Print 2021 Dec. No abstract available.

  PMID: 34561289 DERIVED

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive; Fibrosis

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Nicholas MOORE, MD-PhD

  University Hospital, Bordeaux

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: SCREENING
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 17, 2012
• First Posted: September 25, 2012
• Study Start: April 10, 2013
• Primary Completion: May 20, 2016
• Study Completion: May 20, 2016
• Last Updated: June 9, 2026

Record last verified: 2022-02

Locations

FR (1)